NVS240920C125000
- 0.11
- +0.08+266.67%
Novartis AG Newsroom
Goldman Sachs Remains a Hold on Novartis AG (NOVN)
Novartis AG: Hold Rating Justified Amid Kisqali's Market Potential and FDA Approval
Buy Rating Affirmed: Novartis AG's Strong Growth Outlook and Underestimated Pipeline Potential
Novartis AG (NOVN) Receives a Buy From UBS
Novartis Lower as BofA Downgrades on Risks to Valuation
Novartis Analyst Ratings
B of A Securities Downgrades Novartis to Neutral, Lowers Price Target to $130
BofA Securities Downgrades Novartis AG(NVS.US) to Hold Rating, Raises Target Price to $130
BMO Capital Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $118
Erste Group Maintains Novartis AG(NVS.US) With Buy Rating
Novartis Analyst Ratings
Goldman Sachs Downgrades Novartis to Neutral, Raises Price Target to $121
Goldman Sachs Downgrades Novartis AG(NVS.US) to Hold Rating, Raises Target Price to $121
Novartis Target Cut to $105 From $110 by Jefferies
Novartis Cut to Hold From Buy by Jefferies
Jefferies Downgrades Novartis AG(NVS.US) to Hold Rating, Raises Target Price to $123.5
Novartis AG (NOVN) Receives a Buy From Kepler Capital
The latest pharmaceutical industry rating by S&P reveals that Johnson & Johnson (JNJ.US) and Roche (RHHBY.US) are ranked at the top for superior financial and innovative abilities.
Hold Rating on Novartis AG: Cautious Optimism for Fabhalta Amidst FDA Approval and Market Potential
Berenberg Raises Price Target on Novartis to CHF86 From CHF77, Maintains Hold Rating